Obinutuzumab is used to treat follicular lymphoma. Antibody-dependent cytotoxicity (ADCC) is the main mode by which obinutuzumab works. This article shares the study of the mechanism of ADCC resistance induced by obinutuzumab.
Obinutuzumab
Obinutuzumab is the first individualized, glycosylated type II anti-CD20 monoclonal antibody in the world, which brings new hope to patients due to its higher antibody stability, stronger DCD and ADCC.
|
Advantages
|
Obinutuzumab is a glycosylated second-generation CD20 monoclonal antibody.
Its killing effect on tumors, that is, ADCC, and the ability to directly induce apoptosis of tumor cells is significantly improved.
There is a decline in immune inflammation, which means that the incidence of allergic reactions will be relatively small and mild.
|
|
Side Effect
|
Obinutuzumab will have a slightly higher rate of infection
|
You can find more information about Obinutuzumab by clicking here! And you can find more information on the Rituximab and Obinutuzumab for B-cell Lymphoma page.
Follicular Lymphoma
Follicular lymphoma is one of the most common types of indolent lymphoma. Its characteristic is that the progress is relatively slow and it is not easy to cure. There are three challenges to the treatment of follicular lymphoma. The first is that nearly 20% of patients will develop early progression, resulting in a poor prognosis for patients. The second is that most FL cannot be completely cured, and often recur. Third, there are still some FL that will transform into large B-cell lymphomas.
Fig.1 Classification of targeted therapies for follicular lymphoma.
Method
In this study, obinutuzumab-induced ADCC-resistant cells were established using the non-Hodgkin lymphoma cell line RL. Drug resistance mechanisms were comprehensively analyzed by RNA sequencing.
Results
Here are some results for obinutuzumab in this study:
Fig.2 Establishment and characterization of obinentuzumab-induced ADCC-resistant clones. (Kawasaki, 2022)
Fig.3 Effect of FAS signaling on ADCC sensitivity in RL cells of non-Hodgkin lymphoma. (Kawasaki, 2022)
Fig.4 Effect of obinutuzumab plus prednisolone on sensitivity and antitumor efficacy of ADCC. (Kawasaki, 2022)
Fig.5 Effect of bendamustine plus obinutuzumab on ADCC activity. (Kawasaki, 2022)
Conclusion
In this article, the mechanism of obinutuzumab-induced ADCC resistance was further explored. ADCC resistance can be overcome by combining obinutuzumab with bendamustine or prednisolone. The above studies provide a strong scientific basis for the treatment of follicular lymphoma with obinutuzumab.
Creative Biolabs offers Therapeutic Antibody Glycosylation Engineering Technology to help you further optimize your antibodies, please click to view! If you have any needs regarding ADCC development, please contact us now! scientists at Creative Biolabs are always here to provide you with professional advice and solutions!
References
-
Nath, K.; et al. "Targeted Treatment of Follicular Lymphoma." Journal of personalized medicine. (2021) 11,2 152. 22.
-
Kawasaki, N.; et al. "Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies." Molecular biology reports. (2022): 4421-4433.
All products and services are for Research Use Only. Do Not use in humans.
